Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Below the Biologically Effective Dose.

Glanzmann C, Studer G.

Dtsch Arztebl Int. 2019 Jan 7;116(1-2):9-10. doi: 10.3238/arztebl.2019.0009c. No abstract available.

2.

Neutrophil-lymphocyte ratio complements volumetric staging as prognostic factor in patients treated with definitive radiotherapy for oropharyngeal cancer.

Panje C, Riesterer O, Glanzmann C, Studer G.

BMC Cancer. 2017 Sep 11;17(1):643. doi: 10.1186/s12885-017-3590-0.

3.

Local control and intermediate-term cosmetic outcome following IMRT for nasal tumors : An update.

Mukai Y, Janssen S, Glanzmann C, Holzmann D, Studer G.

Strahlenther Onkol. 2017 Apr;193(4):295-304. doi: 10.1007/s00066-016-1083-8. Epub 2016 Dec 5.

PMID:
27921123
4.

IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80.

Brown ML, Glanzmann C, Huber G, Bredell M, Rordorf T, Studer G.

Strahlenther Onkol. 2016 Aug;192(8):526-36. doi: 10.1007/s00066-016-0986-8. Epub 2016 Jun 15.

5.

Hypofractionated Radiotherapy for Breast Cancer Including Risk-adapted Boost: Update on Tolerance and Efficacy of an Accelerated START A Regime.

Janssen S, Glanzmann C, Lang S, Verlaan S, Streller T, Linsenmeier C, Rades D, Studer G.

Anticancer Res. 2016 May;36(5):2513-22.

PMID:
27127166
6.

Risk profile for osteoradionecrosis of the mandible in the IMRT era.

Studer G, Bredell M, Studer S, Huber G, Glanzmann C.

Strahlenther Onkol. 2016 Jan;192(1):32-9. doi: 10.1007/s00066-015-0875-6. Epub 2015 Aug 12.

7.

Drugs as risk factors of acute kidney injury in critically ill children.

Glanzmann C, Frey B, Vonbach P, Meier CR.

Pediatr Nephrol. 2016 Jan;31(1):145-51. doi: 10.1007/s00467-015-3180-9. Epub 2015 Aug 11.

PMID:
26260379
8.

Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, Collette L, Fourquet A, Maingon P, Valli M, De Winter K, Marnitz S, Barillot I, Scandolaro L, Vonk E, Rodenhuis C, Marsiglia H, Weidner N, van Tienhoven G, Glanzmann C, Kuten A, Arriagada R, Bartelink H, Van den Bogaert W; EORTC Radiation Oncology and Breast Cancer Groups.

N Engl J Med. 2015 Jul 23;373(4):317-27. doi: 10.1056/NEJMoa1415369.

9.

Radiation-induced lower cranial nerve palsy in patients with head and neck carcinoma.

Janssen S, Glanzmann C, Yousefi B, Loewenich K, Huber G, Schmid S, Studer G.

Mol Clin Oncol. 2015 Jul;3(4):811-816. Epub 2015 May 4.

10.

Less may be more: nodal treatment in neck positive head neck cancer patients.

Studer G, Huber GF, Holz E, Glanzmann C.

Eur Arch Otorhinolaryngol. 2016 Jun;273(6):1549-56. doi: 10.1007/s00405-015-3634-5. Epub 2015 Apr 29.

11.

Analysis of medication prescribing errors in critically ill children.

Glanzmann C, Frey B, Meier CR, Vonbach P.

Eur J Pediatr. 2015 Oct;174(10):1347-55. doi: 10.1007/s00431-015-2542-4. Epub 2015 Apr 22.

PMID:
25899070
12.

Carotid artery disease after head and neck radiotherapy.

Thalhammer C, Husmann M, Glanzmann C, Studer G, Amann-Vesti BR.

Vasa. 2015 Jan;44(1):23-30. doi: 10.1024/0301-1526/a000403. Review.

PMID:
25537055
13.

PTV margin definition in hypofractionated IGRT of localized prostate cancer using cone beam CT and orthogonal image pairs with fiducial markers.

Oehler C, Lang S, Dimmerling P, Bolesch C, Kloeck S, Tini A, Glanzmann C, Najafi Y, Studer G, Zwahlen DR.

Radiat Oncol. 2014 Nov 11;9:229. doi: 10.1186/s13014-014-0229-z.

14.

Clinical experience of SIB-IMRT in anal cancer and selective literature review.

Janssen S, Glanzmann C, Bauerfeind P, Stieb S, Studer G, Brown M, Riesterer O.

Radiat Oncol. 2014 Sep 8;9:199. doi: 10.1186/1748-717X-9-199. Review.

15.

Hypofractionated radiotherapy for breast cancer acceleration of the START A treatment regime: intermediate tolerance and efficacy.

Janssen S, Glanzmann C, Lang S, Verlaan S, Streller T, Wisler D, Linsenmeier C, Studer G.

Radiat Oncol. 2014 Jul 24;9:165. doi: 10.1186/1748-717X-9-165.

16.

Risk-adapted partial larynx and/or carotid artery sparing modulated radiation therapy of glottic cancer.

Janssen S, Glanzmann C, Huber G, Studer G.

Radiat Oncol. 2014 Jun 13;9:136. doi: 10.1186/1748-717X-9-136.

17.

Individualized IMRT treatment approach for cervical lymph node metastases of unknown primary.

Janssen S, Glanzmann C, Huber G, Studer G.

Strahlenther Onkol. 2014 Apr;190(4):386-93. doi: 10.1007/s00066-013-0508-x. Epub 2014 Feb 7.

PMID:
24638240
18.

Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.

Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L; EORTC Radiation Oncology Group.

Lancet Oncol. 2014 Feb;15(2):184-90. doi: 10.1016/S1470-2045(13)70599-0. Epub 2014 Jan 17.

PMID:
24440473
19.

Late term tolerance in head neck cancer patients irradiated in the IMRT era.

Studer G, Linsenmeier C, Riesterer O, Najafi Y, Brown M, Yousefi B, Bredell M, Huber G, Schmid S, Studer S, Zwahlen R, Rordorf T, Glanzmann C.

Radiat Oncol. 2013 Nov 5;8:259. doi: 10.1186/1748-717X-8-259.

20.

Volumetric stratification of cT4 stage head and neck cancer.

Studer G, Glanzmann C.

Strahlenther Onkol. 2013 Oct;189(10):867-73. doi: 10.1007/s00066-013-0413-3. Epub 2013 Sep 5.

21.

Volumetric staging in oropharyngeal cancer patients treated with definitive IMRT.

Studer G, Glanzmann C.

Oral Oncol. 2013 Mar;49(3):269-76. doi: 10.1016/j.oraloncology.2012.09.014. Epub 2012 Oct 22.

PMID:
23089460
22.

Follow up after IMRT in oral cavity cancer: update.

Studer G, Brown M, Bredell M, Graetz KW, Huber G, Linsenmeier C, Najafi Y, Riesterer O, Rordorf T, Schmid S, Glanzmann C.

Radiat Oncol. 2012 Jun 11;7:84. doi: 10.1186/1748-717X-7-84.

23.

The use of photon beams of a flattening filter-free linear accelerator for hypofractionated volumetric modulated arc therapy in localized prostate cancer.

Zwahlen DR, Lang S, Hrbacek J, Glanzmann C, Kloeck S, Najafi Y, Streller T, Studer G, Zaugg K, Luetolf UM.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1655-60. doi: 10.1016/j.ijrobp.2011.10.019. Epub 2012 May 7.

PMID:
22572080
24.

Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer.

Studer G, Rordorf T, Glanzmann C.

Radiat Oncol. 2011 Sep 22;6:120. doi: 10.1186/1748-717X-6-120.

25.

Increased recurrences using IMRT in the postoperative setting?

Studer G, Glanzmann C.

Am J Clin Oncol. 2011 Aug;34(4):442. doi: 10.1097/COC.0b013e3181dea9e6. No abstract available.

PMID:
21791985
26.

Risk-adapted dental care prior to intensity-modulated radiotherapy (IMRT).

Studer G, Glanzmann C, Studer SP, Grätz KW, Bredell M, Locher M, Lütolf UM, Zwahlen RA.

Schweiz Monatsschr Zahnmed. 2011;121(3):216-29. English, German.

27.

Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).

Ghadjar P, Simcock M, Studer G, Allal AS, Ozsahin M, Bernier J, Töpfer M, Zimmermann F, Betz M, Glanzmann C, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):524-31. doi: 10.1016/j.ijrobp.2010.11.067. Epub 2011 Feb 16.

PMID:
21300466
28.

Dysphagia in head and neck cancer patients following intensity modulated radiotherapy (IMRT).

Peponi E, Glanzmann C, Willi B, Huber G, Studer G.

Radiat Oncol. 2011 Jan 5;6:1. doi: 10.1186/1748-717X-6-1.

29.

Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT.

Studer G, Brown M, Salgueiro EB, Schmückle H, Romancuk N, Winkler G, Lee SJ, Sträuli A, Kissling B, Dummer R, Glanzmann C.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):110-7. doi: 10.1016/j.ijrobp.2010.05.018. Epub 2010 Aug 21.

PMID:
20732757
30.

Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.

Rothschild S, Bucher SE, Bernier J, Aebersold DM, Zouhair A, Ries G, Lombrieser N, Lippuner T, Lütolf UM, Glanzmann C, Ciernik IF.

Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):126-32. doi: 10.1016/j.ijrobp.2010.01.048. Epub 2010 Jun 18.

PMID:
20646869
31.

Simultaneous integrated boost intensity-modulated radiotherapy (SIB‑IMRT) in nasopharyngeal cancer.

Peponi E, Glanzmann C, Kunz G, Renner C, Tomuschat K, Studer G.

Strahlenther Onkol. 2010 Mar;186(3):135-42. doi: 10.1007/s00066-010-2048-y. Epub 2010 Feb 22.

PMID:
20339827
32.

Surviving hypopharynx-larynx carcinoma in the era of IMRT.

Studer G, Peponi E, Kloeck S, Dossenbach T, Huber G, Glanzmann C.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1391-6. doi: 10.1016/j.ijrobp.2009.07.005. Epub 2010 Jan 7.

PMID:
20056352
33.

Outcome in recurrent head neck cancer treated with salvage-IMRT.

Studer G, Graetz KW, Glanzmann C.

Radiat Oncol. 2008 Dec 17;3:43. doi: 10.1186/1748-717X-3-43.

34.

Prediction of distant metastasis in head neck cancer patients: implications for induction chemotherapy and pre-treatment staging?

Studer G, Seifert B, Glanzmann C.

Strahlenther Onkol. 2008 Nov;184(11):580-5. doi: 10.1007/s00066-008-1951-y. Epub 2008 Nov 19.

PMID:
19016016
35.

Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer: in regard to Schoenfeld et al. (Int J Radiat Oncol Biol Phys 2008;71:377-385).

Studer GM, Glanzmann C.

Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1271-2; author reply 1272. doi: 10.1016/j.ijrobp.2008.07.022. No abstract available.

PMID:
18954722
36.
37.

[Recommendations for dental care prior to intensity-modulated radiotherapy (IMRT). Adaptation of the University Hospital Zurich (USZ) guidelines].

Studer G, Glanzmann C, Studer SP, Grätz KW, Lütolf UM, Zwahlen RA; UniversitätsSpital Zürich.

Schweiz Monatsschr Zahnmed. 2007;117(6):637-47. French, German.

38.

Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma.

Oehler-Jänne C, Seifert B, Lütolf UM, Studer G, Glanzmann C, Ciernik IF.

Brachytherapy. 2007 Jul-Sep;6(3):218-26.

PMID:
17681244
39.

Locoregional failure analysis in head-and-neck cancer patients treated with IMRT.

Studer G, Luetolf UM, Glanzmann C.

Strahlenther Onkol. 2007 Aug;183(8):417-23; discussion 424-5.

40.

In response to Dr. Merav A. Ben-David et al. ("Lack of osteoradionecrosis of the mandible after IMRT," Int J Radiat Oncol Biol Phys 2007:In Press).

Studer G, Graetz KW, Glanzmann C.

Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1583-4. No abstract available.

PMID:
17674994
41.

PET/CT staging followed by Intensity-Modulated Radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison.

Rothschild S, Studer G, Seifert B, Huguenin P, Glanzmann C, Davis JB, Lütolf UM, Hany TF, Ciernik IF.

Radiat Oncol. 2007 Jun 9;2:22.

42.

Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT.

Studer G, Lütolf UM, El-Bassiouni M, Rousson V, Glanzmann C.

Acta Oncol. 2007;46(3):386-94.

PMID:
17450476
43.

In regards to Dr. Garden et al. (Int J Radiat Oncol Biol Phys 2007;67:438-444).

Studer G, Glanzmann C.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):313-4. No abstract available.

PMID:
17448885
44.

IMRT in oral cavity cancer.

Studer G, Zwahlen RA, Graetz KW, Davis BJ, Glanzmann C.

Radiat Oncol. 2007 Apr 12;2:16.

45.

Postoperative IMRT in head and neck cancer.

Studer G, Furrer K, Davis BJ, Stoeckli SS, Zwahlen RA, Luetolf UM, Glanzmann C.

Radiat Oncol. 2006 Oct 19;1:40.

46.

IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients.

Studer G, Huguenin PU, Davis JB, Kunz G, Lütolf UM, Glanzmann C.

Radiat Oncol. 2006 Mar 31;1:7.

47.

IMRT in hypopharyngeal tumors.

Studer G, Lütolf UM, Davis JB, Glanzmann C.

Strahlenther Onkol. 2006 Jun;182(6):331-5.

PMID:
16703288
48.

Osteoradionecrosis of the mandible: minimized risk profile following intensity-modulated radiation therapy (IMRT).

Studer G, Studer SP, Zwahlen RA, Huguenin P, Grätz KW, Lütolf UM, Glanzmann C.

Strahlenther Onkol. 2006 May;182(5):283-8.

PMID:
16673062
49.

Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.

Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thöni A, Ozsahin M, Bernier J, Töpfer M, Kann R, Meier UR, Thum P, Bieri S, Notter M, Lombriser N, Glanzmann C.

J Clin Oncol. 2004 Dec 1;22(23):4665-73. Epub 2004 Nov 8. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15534360
50.

Differential activation of the phosphatidylinositol 3'-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells.

Zingg D, Riesterer O, Fabbro D, Glanzmann C, Bodis S, Pruschy M.

Cancer Res. 2004 Aug 1;64(15):5398-406.

Supplemental Content

Loading ...
Support Center